

IPu

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: April 5, 2005

Signature: _____

(Lynn L. Janulis)

Docket No.: 01017/39555
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Mehta *et al.*

Application No.: 10/694,579

Art Unit: 1647

Filed: October 27, 2003

Examiner: James Jason Galvez

For: G-CSF THERAPY AS AN ADJUNCT TO
REPERFUSION THERAPY IN THE
TREATMENT OF ACUTE MYOCARDIAL
INFARCTION

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In compliance with 37 C.F.R. §1.97 and the continuing duty of disclosure under 37 C.F.R. §1.56, a copy of a Supplemental Information Disclosure Statement and Form PTO/SB/08 are hereby submitted by the Applicants for consideration in connection with the above-identified patent application. The relevant documents were cited to the Applicants by way of a European Search Report in a related application. All documents listed on the enclosed PTO/SB/08 are enclosed herewith.

This Supplemental Information Disclosure Statement is not intended to be an admission that this art is relevant, or that other relevant art does not exist, or that any of the information disclosed herein constitutes prior art under 35 U.S.C. §102 and §103.

No fee is required for submission of this statement because the enclosed documents were cited in a search report mailed February 2, 2005. Thus, no item of information was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this statement. Should the Patent Office determine that a fee is due for consideration of this Supplemental Information Disclosure Statement, however, the Patent Office is hereby authorized to charge that fee to Deposit Account 13-2855. A copy of this paper is enclosed.

Dated: April 5, 2005

Respectfully submitted,

By 

Lynn L. Janulis, Ph.D.

Registration No.: 53,066

Agent for Applicants


MARSHALL, GERSTEIN & BORUN LLP

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/694,579
				Filing Date	October 27, 2003
				First Named Inventor	Mehta et al.
				Art Unit	1614
				Examiner Name	To be determined
Sheet	1	of	2	Attorney Docket Number	01017/39555

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	B30	EP 1129720	09-05-2001	Pfizer Products Inc.		
	B31	EP 1327449	07-16-2003	Chugai Seiyaku Kabushiki Kaisha		
	B32	WO 88/00969	02-11-1988	Immunex Corporation		
	B33	WO 92/06707	04-30-1992	Amgen Inc.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C23	AMBLER et al., "Integration of bone marrow-derived stem cells into infarcted myocardium following ischemia-reperfusion in mice," Abstract No. 413.7, <i>FASEB Journal</i> 17:4-5, 2003.	
	C24	ENGELMANN et al., "Placebo-controlled, randomized, double-blind study on the efficacy of bone-marrow stem cell mobilization induced by granulocyte-colony stimulating factor (G-CSF) on improvement of ischemic heart failure undergoing delayed revascularization for ST segment elevation myocardial infarction (STEM)," Abstract No. 2829, <i>Circulation</i> 108 (17) Suppl.:IV-622, 2003.	
	C25	GOLTERMANN, "Reperfusion of acute coronary syndromes and myocardial infarction," <i>Air Medical Journal</i> 19:47-49, 2000.	
	C26	HELLSTRÖM-LINDBERG et al., "Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: Results from a randomized phase II study and long-term follow-up of 71 patients," <i>Blood</i> 92:68-75, 1998.	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/694,579
				Filing Date	October 27, 2003
				First Named Inventor	Mehta et al.
				Art Unit	1614
				Examiner Name	To be determined
Sheet	2	of	2	Attorney Docket Number	01017/39555

C27	KURAMOCHI et al., "Granulocyte-colony stimulating factor (G-CSF) administration improves cardiac function after myocardial infarction in mice without altering cardiomyocyte regeneration," Abstract No. 99, <i>Circulation</i> , 106:19 (Suppl.): II-20, 2002.	
C28	LI et al., "Efficiency of granulocyte colony stimulating factor (G-CSF) on cardiac function and cytokines in rat model of acute myocardial infarction," Abstract No. 3P-0648, <i>Artherosclerosis Supplements</i> , 4 (2):204, 2003.	
C29	MEHTA et al., "Early administration of a filgrastim following experimental myocardial infarction in a porcine ischemia reperfusion model may help myocardial repair," Abstract No. 4328, <i>Blood</i> 102:154b-155b, 2003.	
C30	MINATOBUCHI et al., "Acceleration of the healing process and myocardial regeneration may be important as a mechanism of improvement of cardiac function and remodeling by postinfarction granulocyte colony-stimulating factor treatment," <i>Circulation</i> , 109:2572-2580, 2004.	
C31	MINATOBUCHI et al., "Myocardial infarction itself induces cardiomyocyte regeneration from bone marrow cells, and post-ischemic G-CSF treatment improves cardiac dysfunction via acceleration of the process," Abstract No. 666, <i>Circulation</i> 106 (19) Suppl.:II-132-133, 2002.	
C32	SCHWARTZ et al., "Autologous stem cells for functional myocardial repair," <i>Heart Failure Reviews</i> , 8:237-245, 2003.	
C33	International Search Report and Written Opinion from the European Patent Office (International Search Authority) for PCT/US2004/031704 (counterpart PCT application), mailed February 2, 2005.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--